Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Dec

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Peter Clark, MA, MD, FRCP: A Payer Perspective

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer

Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns

Data Published on Incidence of Immune Checkpoint Inhibitor-Associated ITP

Lymphocyte Kinetics After CAR T Infusion Predict Survival Outcomes in Non-Hodgkin Lymphoma

CD123-Targeting ADC Shows Activity in AML and BPDCN